Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Figure out How to Pick a SUV with Senior-Accommodating Tech Elements - 2NASA's Perseverance Mars rover could break the record for miles driven on another planet
- 3Carrying on with a Sans plastic Way of life: Individual Examinations in Maintainability
- 4How to disinfect if the stomach bug hits your home
- 5Over 250,000 cases of shredded cheese recalled over possible metal fragments
- Holiday season sees uptick in norovirus cases, according to CDC
- Rights group: At least 2,500 deaths during protest crackdown in Iran
- NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century
- This cafe takes orders in sign language. It's cherished by the Deaf community
- ‘Ukrainian housewives’ and Skyranger delays – German defense poster child Rheinmetall is in hot water
- 6 Financial plan 3D Printers with the Best Worth
- Chevron Says Damage at Wheatstone LNG Will Hamper Restart
- The most effective method to Recognize an Excellent Lab Precious stone
- Architect Frank Gehry has died: See his most iconic buildings
